Acquisition of Clinomics Biosciences, Inc Placing to raise £1.915 million

Cytomyx Holdings Plc (“Cytomyx” or “Company”) is pleased to announce that it has conditionally agreed to acquire the entire issued ordinary share capital of Clinomics Biosciences, Inc (“Clinomics”) and at the same time has raised £1,915,000 by way of a placing with institutional investors.

Clinomics was founded to capitalise upon the opportunity to link recently acquired knowledge about genes and proteins to their relevance in human disease through the use of human tissue. Central to being able to achieve this has been the creation by Clinomics of a large (>200,000) collection of highly characterised human tissue samples, described as its Biorepository.  These samples span a wide range of common diseases, including many forms and stages of cancer, neurological disorders and heart disease.

Clinomics enables its clients in the pharmaceutical industry to access the information contained within these samples by providing Contract Research Services and increasingly through the sale of research products developed using the Biorepository. It has also pioneered the development of an emerging new technology known as Tissue Microarrays, an area in which it currently has three granted US patents. These enable researchers to simultaneously study hundreds of individual tissue samples in parallel to establish the relative levels of protein expression in those samples and thereby draw conclusions as to the relevance of these proteins to disease.

There are significant similarities between Clinomics and Cytomyx including customer profiles albeit in different geographical territories and highly complementary technological capabilities.

Cytomyx intends to appoint Stephen Turner, 58, co-founder and Chief Executive Officer of Clinomics, as a non-executive director of the Company.  Mr Turner has over 25 years experience in the formation, development and management of Life Science businesses. Prior to co-founding Clinomics he founded several other successful businesses and has completed numerous public financings to fund them.  Mr. Turner will be responsible for overseeing the US operations and for developing further corporate activity in the USA.

Commenting on the proposed acquisition, Cytomyx’ Chief Executive Mike Kerins said “This is an important strategic acquisition for the Group. We have been working closely with Clinomics throughout the past year and see a great opportunity to create value by combining it with our existing Group companies.

Clinomics is a pioneering business that has built a hugely valuable resource, which has already demonstrated its value to major pharmaceutical companies. The drug discovery industry now needs to be able to link information created through years of investment in genomic technologies, to the role these genes play in disease.  The best way to achieve this is through access to a large collection of highly characterised human clinical samples such as that which Clinomics has built.

We will also benefit greatly from the access that Clinomics can provide to the US life science market for our existing product lines. We have been building a portfolio of drug discovery related products over the past two years and our link with Clinomics will enable us to access the key market for these directly.  We plan to build a US based sales force both for Clinomics’ existing products and for our own new product lines”.

Mr. Turner said "We are extremely pleased to achieve this Agreement with Cytomyx, a rapidly-growing business strategically located in the UK.  With operations in the US and Europe, our combined company is well-positioned to develop a leading global Life Sciences franchise.”

background information

Cytomyx Holdings PLC (AIM:CYX) is a rapidly growing life science company.  Its three current operating subsidiaries, Cambridge Bioscience Ltd, Cytocell Technologies Ltd and Cytomyx Ltd, develop and market a wide range of products and services to customers in the pharmaceutical, diagnostics and academic research markets.

Based in Cambridge, UK, Cytomyx has been listed on London’s Alternative Investment Market since 2001.

Company Contact

Karen Chandler-Smith

Cytomyx Holdings Plc

6-7 Technopark

Cambridge, CB5 8PB

United Kingdom

Tel: +44 1223 508191

Fax: +44 1223 508198

info@cytomyx.com

http://www.cytomyx.com